Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Myositis Mysteries

Kathleen M. Coyle, MD, Paul H. Plotz, MD, and Mark F. Gourley, MD  |  Issue: January 2008  |  January 1, 2008

Both PM and DM present subacutely over weeks to months with proximal muscle weakness. The photosensitive skin manifestations of DM include facial erythroderma without sparing of the nasolabial folds that is typical in lupus erythematosus; heliotrope rash around the eyes; Gottron’s rash/papules (see Figure 2, below); and shawl and v-neck signs. Patients with MSAs can be categorized by typical features associated with these antibodies. See Table 3 (p. 22) for a list of features associated with particular autoantibodies.

In contrast to the presentation of PM and DM, the onset and progression of IBM is characteristically slow, occurring over months to years. Asymmetric weakness, dysphagia, frequent falling, and distal as well as proximal muscle weakness and wasting are hallmarks of this IIM subset.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

IIM can present in overlap with other rheumatic diseases, including systemic lupus erythematosus, progressive systemic sclerosis (scleroderma), Sjögren’s syndrome, and RA. The onset of myositis symptoms can occur at, before, or after diagnosis of these diseases. Overlap with IBM is far less common, but has been reported.

TABLE 1. Myositis Masqueraders
click for large version
TABLE 1. Myositis Masqueraders5

The association of IIM with malignancy is well recognized. In a review of four studies comprising 1,078 myositis patients and a comparable number of controls, the overall odds ratio (OR) for the association of cancer with DM was 4.4 (95%, confidence interval [CI] 3.0, 6.6) and with PM the OR was 2.1 (95% CI 1.4, 3.3).6 Malignancies are predominantly adenocarcinomas and usually develop within one year before or after myositis onset, but have been reported to occur up to five years later.7 Therefore, age-appropriate cancer screening and ongoing surveillance with a lowered threshold for further investigation is mandated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Approximately 30% of DM cases present without clinically apparent muscle weakness, the majority of which progress months or years later to clinical myositis.8 Patients without evidence of muscle weakness or serum muscle enzyme abnormalities are classified as dermatomyositis sine myositis or amyopathic DM. These patients can develop interstitial lung disease (ILD) which can be rapidly progressive, heralding a poor prognosis.9,10

The importance of evaluation for toxic myopathies cannot be stressed enough, for as a group toxins represent the most common etiology of myopathy. In an elegant review of this topic, Walsh and Amato classified the toxic myopathies to date according to presumed pathogenic mechanism into seven categories:11

  1. Necrotizing myopathy: Alcohol, anti-lipemic agents (statins and fibrates), cyclosporin, labetolol, propofol, illicit drugs (cocaine, heroin, amphetamines), and controlled substances (meperidine, pentazocine);
  2. Amphiphilic: Amiodarone, chloroquine, and hydroxychloroquine;
  3. Antimicrotubular: Colchicine and vincristine;
  4. Mitochondrial myopathy: Zidovudine;
  5. Inflammatory myopathy: L-tryptophan, D-penicillamine, cimetidine, L-dopa, phenytoin, lamotrigine, interferon-α, hydroxyurea, and imatinib;
  6. Hypokalemic myopathy: Diuretics, laxatives, amphotericin, toluene abuse, licorice, corticosteroids, and alcohol abuse; and
  7. Unknown: Critical illness myopathy (corticosteroids, nondepolarizing neuromuscular blocking agents, and sepsis), omeprazole, isoretinoin, finasteride, and emetine.

Obtaining a family history of similar symptoms and neuromuscular disease is important; a positive response is most likely indicative of pathology other than IIM, such as in the muscular dystrophy in the case study above. A notable exception is IBM, because both idiopathic and familial forms exist.

Laboratory Tests

Muscle enzymes: As noted above, elevations of serum concentration of intracellular muscle components (CK, aldolase, AST, ALT, LDH, and myoglobin) generally accompany myositis. In IBM, serum CK correlates poorly with disease acuity and severity. It is normal in 25% of patients and, if abnormal, it is generally only slightly elevated.12

FIGURE 3: Mechanics hands. Roughening of the radial sides of the fingers seen in patients with anti–aminoacyl-tRNA synthetase (anti–Jo-1) autoantibodies.
FIGURE 3: Mechanics hands. Roughening of the radial sides of the fingers seen in patients with anti–aminoacyl-tRNA synthetase (anti–Jo-1) autoantibodies.

Tests commonly called “liver function tests” actually test for liver-associated enzymes such as AST, ALT, and LDH—which are also found in muscle. Unfortunately, it is common for patients to present to rheumatologists after a liver biopsy is performed due to elevated “liver function tests” resulting from active myositis. In this case, the liver biopsy is normal. Also remember that, when monitoring a patient with active myositis and elevated CK being treated with MTX, increased AST and ALT are more likely to reflect active disease than MTX-induced hepatic toxicity.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsMyositis Tagged with:Diagnostic Criteriaidiopathic inflammatory myopathymyositisPathogenesisPatientspolymyositisrheumatologyTreatment

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Tashatuvango / shutterstock.com

    Myositis-Specific Antibodies Identified

    January 16, 2020

    The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

    Inflammatory Myopathies Difficult to Diagnose, Treat

    December 1, 2013

    Without a single set of diagnostic criteria for identifying polymyositis, dermatomyositis, or myositis and scant evidence-based therapeutic guidelines, these rare muscle diseases can be hard to manage

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences